Phenytoin and Cyclosporine A Specifically Regulate Macrophage Phenotype and Expression of Platelet-Derived Growth Factor and Interleukin-1 in Vitro and in Vivo: Possible Molecular Mechanism of Drug-Induced Gingival Hyperplasia

Anthony M. Iacopino, Deborah Doxey, Christopher W Cutler, Salvador Nares, Kim Stoever, James Fojt, Andrea Gonzales, Russell E. Dill

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Phenytoin (PHT) is an anticonvulsant drug commonly used for the prevention of seizures. A common side effect of PHT therapy is gingival hyperplasia, occasionally so severe that it requires surgical intervention. Cyclosporine A (CSA) is a drug widely used for the control of rejection phenomena following solid organ and bone marrow transplantation. A frequent side effect of CSA administration is gingival overgrowth. As yet, the molecular mechanisms of drug-induced gingival hyperplasia are unknown although it has been postulated that certain drugs increase fibroblastic activity through alterations in levels of various growth factors and cytokines. The purpose of this study was to: 1) evaluate monocyte/macrophage platelet-derived growth factor (PDGF) and interleukin (IL)-1β production in vitro after exposure to CSA; 2) determine the levels of PDGF-B and IL-1β gene expression in minimally inflamed gingival tissues of control patients and PHT-treated patients exhibiting gingival overgrowth as well as patients with severe gingival inflammation; and 3) combine characterization of macrophage phenotype with clinical presentation and expression of PDGF-B and IL-1β in gingival tissues from the control and PHT-treated patients. For the in vitro studies, commercial ELISA kits were used to measure PDGF-A/PDGF-B and IL-1β levels in conditioned media from rat and human monocyte/macrophage cell cultures. CSA caused a significant elevation of PDGF but did not cause any changes in IL-1β levels. For the in vivo studies, quantitative competitive reverse transcription polymerase chain reaction (QC-RTPCR) techniques were utilized to measure PDGF-B and IL-1β mRNA levels in experimental groups. PHT-treated patients exhibiting gingival overgrowth demonstrated a significant increase in PDGF-B mRNA compared with minimally inflamed controls. Patients with severe gingival inflammation also demonstrated a significant increase in PDGF-B mRNA however, PHT-induced PDGF-B upregulation is approximately 6 times larger than PDGF-B upregulation produced by inflammation alone. PHT-treated patients exhibiting gingival overgrowth demonstrated no significant increase in IL-1β mRNA; however, IL-1β mRNA levels in the severely inflamed gingival samples demonstrated a significant increase. Additionally, for the clinical samples, macrophage phenotype was characterized immunohistochemically in adjacent sections using specific monoclonal antibodies for inflammatory and reparative/proliferative phenotypes. There were no significant differences in the numbers of either macrophage phenotype in minimally inflamed gingival tissues; however, in the severely inflammed tissue, there was a significant increase in the inflammatory macrophage phenotype and in the hyperplastic gingival tissue, there was a significant increase in the reparative/proliferative macrophage phenotype. The results of this investigation indicate that the clinical presentation of inflamed and hyperplastic gingival tissues is associated with specific macrophage phenotypes which express the pro-inflammatory cytokine IL-1β in inflamed tissues or the essential polypeptide growth factor PDGF-B in PHT-induced hyperplastic tissues.

Original languageEnglish (US)
Pages (from-to)73-83
Number of pages11
JournalJournal of Periodontology
Volume68
Issue number1
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Gingival Hyperplasia
Proto-Oncogene Proteins c-sis
Platelet-Derived Growth Factor
Phenytoin
Interleukin-1
Cyclosporine
Macrophages
Gingival Overgrowth
Phenotype
Pharmaceutical Preparations
Messenger RNA
Inflammation
Monocytes
Intercellular Signaling Peptides and Proteins
Up-Regulation
Cytokines
In Vitro Techniques
Conditioned Culture Medium
Bone Marrow Transplantation
Anticonvulsants

Keywords

  • Cyclosporine A/adverse effects
  • Gene expression
  • Gingival hyperplasia/etiology
  • Growth factor, platelet-derived
  • Interleukin-1
  • Macrophages
  • Phenytoin/adverse effects

ASJC Scopus subject areas

  • Periodontics

Cite this

Phenytoin and Cyclosporine A Specifically Regulate Macrophage Phenotype and Expression of Platelet-Derived Growth Factor and Interleukin-1 in Vitro and in Vivo : Possible Molecular Mechanism of Drug-Induced Gingival Hyperplasia. / Iacopino, Anthony M.; Doxey, Deborah; Cutler, Christopher W; Nares, Salvador; Stoever, Kim; Fojt, James; Gonzales, Andrea; Dill, Russell E.

In: Journal of Periodontology, Vol. 68, No. 1, 01.01.1997, p. 73-83.

Research output: Contribution to journalArticle

@article{4cadbad8c712480f8169eeff0e648034,
title = "Phenytoin and Cyclosporine A Specifically Regulate Macrophage Phenotype and Expression of Platelet-Derived Growth Factor and Interleukin-1 in Vitro and in Vivo: Possible Molecular Mechanism of Drug-Induced Gingival Hyperplasia",
abstract = "Phenytoin (PHT) is an anticonvulsant drug commonly used for the prevention of seizures. A common side effect of PHT therapy is gingival hyperplasia, occasionally so severe that it requires surgical intervention. Cyclosporine A (CSA) is a drug widely used for the control of rejection phenomena following solid organ and bone marrow transplantation. A frequent side effect of CSA administration is gingival overgrowth. As yet, the molecular mechanisms of drug-induced gingival hyperplasia are unknown although it has been postulated that certain drugs increase fibroblastic activity through alterations in levels of various growth factors and cytokines. The purpose of this study was to: 1) evaluate monocyte/macrophage platelet-derived growth factor (PDGF) and interleukin (IL)-1β production in vitro after exposure to CSA; 2) determine the levels of PDGF-B and IL-1β gene expression in minimally inflamed gingival tissues of control patients and PHT-treated patients exhibiting gingival overgrowth as well as patients with severe gingival inflammation; and 3) combine characterization of macrophage phenotype with clinical presentation and expression of PDGF-B and IL-1β in gingival tissues from the control and PHT-treated patients. For the in vitro studies, commercial ELISA kits were used to measure PDGF-A/PDGF-B and IL-1β levels in conditioned media from rat and human monocyte/macrophage cell cultures. CSA caused a significant elevation of PDGF but did not cause any changes in IL-1β levels. For the in vivo studies, quantitative competitive reverse transcription polymerase chain reaction (QC-RTPCR) techniques were utilized to measure PDGF-B and IL-1β mRNA levels in experimental groups. PHT-treated patients exhibiting gingival overgrowth demonstrated a significant increase in PDGF-B mRNA compared with minimally inflamed controls. Patients with severe gingival inflammation also demonstrated a significant increase in PDGF-B mRNA however, PHT-induced PDGF-B upregulation is approximately 6 times larger than PDGF-B upregulation produced by inflammation alone. PHT-treated patients exhibiting gingival overgrowth demonstrated no significant increase in IL-1β mRNA; however, IL-1β mRNA levels in the severely inflamed gingival samples demonstrated a significant increase. Additionally, for the clinical samples, macrophage phenotype was characterized immunohistochemically in adjacent sections using specific monoclonal antibodies for inflammatory and reparative/proliferative phenotypes. There were no significant differences in the numbers of either macrophage phenotype in minimally inflamed gingival tissues; however, in the severely inflammed tissue, there was a significant increase in the inflammatory macrophage phenotype and in the hyperplastic gingival tissue, there was a significant increase in the reparative/proliferative macrophage phenotype. The results of this investigation indicate that the clinical presentation of inflamed and hyperplastic gingival tissues is associated with specific macrophage phenotypes which express the pro-inflammatory cytokine IL-1β in inflamed tissues or the essential polypeptide growth factor PDGF-B in PHT-induced hyperplastic tissues.",
keywords = "Cyclosporine A/adverse effects, Gene expression, Gingival hyperplasia/etiology, Growth factor, platelet-derived, Interleukin-1, Macrophages, Phenytoin/adverse effects",
author = "Iacopino, {Anthony M.} and Deborah Doxey and Cutler, {Christopher W} and Salvador Nares and Kim Stoever and James Fojt and Andrea Gonzales and Dill, {Russell E.}",
year = "1997",
month = "1",
day = "1",
language = "English (US)",
volume = "68",
pages = "73--83",
journal = "Journal of Periodontology",
issn = "0022-3492",
publisher = "American Academy of Periodontology",
number = "1",

}

TY - JOUR

T1 - Phenytoin and Cyclosporine A Specifically Regulate Macrophage Phenotype and Expression of Platelet-Derived Growth Factor and Interleukin-1 in Vitro and in Vivo

T2 - Possible Molecular Mechanism of Drug-Induced Gingival Hyperplasia

AU - Iacopino, Anthony M.

AU - Doxey, Deborah

AU - Cutler, Christopher W

AU - Nares, Salvador

AU - Stoever, Kim

AU - Fojt, James

AU - Gonzales, Andrea

AU - Dill, Russell E.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Phenytoin (PHT) is an anticonvulsant drug commonly used for the prevention of seizures. A common side effect of PHT therapy is gingival hyperplasia, occasionally so severe that it requires surgical intervention. Cyclosporine A (CSA) is a drug widely used for the control of rejection phenomena following solid organ and bone marrow transplantation. A frequent side effect of CSA administration is gingival overgrowth. As yet, the molecular mechanisms of drug-induced gingival hyperplasia are unknown although it has been postulated that certain drugs increase fibroblastic activity through alterations in levels of various growth factors and cytokines. The purpose of this study was to: 1) evaluate monocyte/macrophage platelet-derived growth factor (PDGF) and interleukin (IL)-1β production in vitro after exposure to CSA; 2) determine the levels of PDGF-B and IL-1β gene expression in minimally inflamed gingival tissues of control patients and PHT-treated patients exhibiting gingival overgrowth as well as patients with severe gingival inflammation; and 3) combine characterization of macrophage phenotype with clinical presentation and expression of PDGF-B and IL-1β in gingival tissues from the control and PHT-treated patients. For the in vitro studies, commercial ELISA kits were used to measure PDGF-A/PDGF-B and IL-1β levels in conditioned media from rat and human monocyte/macrophage cell cultures. CSA caused a significant elevation of PDGF but did not cause any changes in IL-1β levels. For the in vivo studies, quantitative competitive reverse transcription polymerase chain reaction (QC-RTPCR) techniques were utilized to measure PDGF-B and IL-1β mRNA levels in experimental groups. PHT-treated patients exhibiting gingival overgrowth demonstrated a significant increase in PDGF-B mRNA compared with minimally inflamed controls. Patients with severe gingival inflammation also demonstrated a significant increase in PDGF-B mRNA however, PHT-induced PDGF-B upregulation is approximately 6 times larger than PDGF-B upregulation produced by inflammation alone. PHT-treated patients exhibiting gingival overgrowth demonstrated no significant increase in IL-1β mRNA; however, IL-1β mRNA levels in the severely inflamed gingival samples demonstrated a significant increase. Additionally, for the clinical samples, macrophage phenotype was characterized immunohistochemically in adjacent sections using specific monoclonal antibodies for inflammatory and reparative/proliferative phenotypes. There were no significant differences in the numbers of either macrophage phenotype in minimally inflamed gingival tissues; however, in the severely inflammed tissue, there was a significant increase in the inflammatory macrophage phenotype and in the hyperplastic gingival tissue, there was a significant increase in the reparative/proliferative macrophage phenotype. The results of this investigation indicate that the clinical presentation of inflamed and hyperplastic gingival tissues is associated with specific macrophage phenotypes which express the pro-inflammatory cytokine IL-1β in inflamed tissues or the essential polypeptide growth factor PDGF-B in PHT-induced hyperplastic tissues.

AB - Phenytoin (PHT) is an anticonvulsant drug commonly used for the prevention of seizures. A common side effect of PHT therapy is gingival hyperplasia, occasionally so severe that it requires surgical intervention. Cyclosporine A (CSA) is a drug widely used for the control of rejection phenomena following solid organ and bone marrow transplantation. A frequent side effect of CSA administration is gingival overgrowth. As yet, the molecular mechanisms of drug-induced gingival hyperplasia are unknown although it has been postulated that certain drugs increase fibroblastic activity through alterations in levels of various growth factors and cytokines. The purpose of this study was to: 1) evaluate monocyte/macrophage platelet-derived growth factor (PDGF) and interleukin (IL)-1β production in vitro after exposure to CSA; 2) determine the levels of PDGF-B and IL-1β gene expression in minimally inflamed gingival tissues of control patients and PHT-treated patients exhibiting gingival overgrowth as well as patients with severe gingival inflammation; and 3) combine characterization of macrophage phenotype with clinical presentation and expression of PDGF-B and IL-1β in gingival tissues from the control and PHT-treated patients. For the in vitro studies, commercial ELISA kits were used to measure PDGF-A/PDGF-B and IL-1β levels in conditioned media from rat and human monocyte/macrophage cell cultures. CSA caused a significant elevation of PDGF but did not cause any changes in IL-1β levels. For the in vivo studies, quantitative competitive reverse transcription polymerase chain reaction (QC-RTPCR) techniques were utilized to measure PDGF-B and IL-1β mRNA levels in experimental groups. PHT-treated patients exhibiting gingival overgrowth demonstrated a significant increase in PDGF-B mRNA compared with minimally inflamed controls. Patients with severe gingival inflammation also demonstrated a significant increase in PDGF-B mRNA however, PHT-induced PDGF-B upregulation is approximately 6 times larger than PDGF-B upregulation produced by inflammation alone. PHT-treated patients exhibiting gingival overgrowth demonstrated no significant increase in IL-1β mRNA; however, IL-1β mRNA levels in the severely inflamed gingival samples demonstrated a significant increase. Additionally, for the clinical samples, macrophage phenotype was characterized immunohistochemically in adjacent sections using specific monoclonal antibodies for inflammatory and reparative/proliferative phenotypes. There were no significant differences in the numbers of either macrophage phenotype in minimally inflamed gingival tissues; however, in the severely inflammed tissue, there was a significant increase in the inflammatory macrophage phenotype and in the hyperplastic gingival tissue, there was a significant increase in the reparative/proliferative macrophage phenotype. The results of this investigation indicate that the clinical presentation of inflamed and hyperplastic gingival tissues is associated with specific macrophage phenotypes which express the pro-inflammatory cytokine IL-1β in inflamed tissues or the essential polypeptide growth factor PDGF-B in PHT-induced hyperplastic tissues.

KW - Cyclosporine A/adverse effects

KW - Gene expression

KW - Gingival hyperplasia/etiology

KW - Growth factor, platelet-derived

KW - Interleukin-1

KW - Macrophages

KW - Phenytoin/adverse effects

UR - http://www.scopus.com/inward/record.url?scp=0030614422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030614422&partnerID=8YFLogxK

M3 - Article

C2 - 9029455

AN - SCOPUS:0030614422

VL - 68

SP - 73

EP - 83

JO - Journal of Periodontology

JF - Journal of Periodontology

SN - 0022-3492

IS - 1

ER -